[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CU20110136A7 - Régimen de dosificación para un agonista de los receptores de s1p - Google Patents

Régimen de dosificación para un agonista de los receptores de s1p

Info

Publication number
CU20110136A7
CU20110136A7 CU20110136A CU20110136A CU20110136A7 CU 20110136 A7 CU20110136 A7 CU 20110136A7 CU 20110136 A CU20110136 A CU 20110136A CU 20110136 A CU20110136 A CU 20110136A CU 20110136 A7 CU20110136 A7 CU 20110136A7
Authority
CU
Cuba
Prior art keywords
dosage regime
receiver agonist
agonist
receiver
dosage
Prior art date
Application number
CU20110136A
Other languages
English (en)
Inventor
Michael Looby
Olivier David
Thomas Dumortier
Robert Schmouder
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20110136(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20110136A7 publication Critical patent/CU20110136A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los moduladores o agonistas de los receptores de S1P se administran siguiendo un régimen de dosificación en donde, durante los días iniciales del tratamiento, la dosificación diaria es más baja que la dosificación diaria convencional.
CU20110136A 2008-12-22 2011-06-22 Régimen de dosificación para un agonista de los receptores de s1p CU20110136A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967208P 2008-12-22 2008-12-22
US21853009P 2009-06-19 2009-06-19
US24671509P 2009-09-29 2009-09-29

Publications (1)

Publication Number Publication Date
CU20110136A7 true CU20110136A7 (es) 2012-01-31

Family

ID=41667217

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20110136A CU20110136A7 (es) 2008-12-22 2011-06-22 Régimen de dosificación para un agonista de los receptores de s1p

Country Status (42)

Country Link
US (11) US20100160259A1 (es)
EP (6) EP3409274B1 (es)
JP (7) JP2012513401A (es)
KR (1) KR101347919B1 (es)
CN (1) CN102264359A (es)
AR (1) AR074826A1 (es)
AU (1) AU2009330176C9 (es)
BR (1) BRPI0923500A2 (es)
CA (1) CA2747802C (es)
CL (2) CL2011001529A1 (es)
CO (1) CO6390117A2 (es)
CR (1) CR20110274A (es)
CU (1) CU20110136A7 (es)
CY (4) CY1116990T1 (es)
DK (3) DK3409274T3 (es)
EA (1) EA201100978A1 (es)
EC (1) ECSP11011222A (es)
ES (3) ES2552823T3 (es)
FR (1) FR20C1060I1 (es)
HN (1) HN2011001759A (es)
HR (3) HRP20151190T1 (es)
HU (4) HUE048717T4 (es)
IL (3) IL213170A0 (es)
LT (3) LT3409274T (es)
LU (1) LUC00183I2 (es)
MA (1) MA32981B1 (es)
ME (2) ME03802B (es)
MX (2) MX2011006623A (es)
NO (1) NO2020038I1 (es)
NZ (1) NZ593065A (es)
PE (1) PE20120337A1 (es)
PL (3) PL2379067T3 (es)
PT (3) PT3409274T (es)
RS (2) RS59857B1 (es)
SG (1) SG171404A1 (es)
SI (3) SI2379067T1 (es)
SM (2) SMT202000441T1 (es)
TN (1) TN2011000272A1 (es)
TW (1) TW201028143A (es)
UY (1) UY32352A (es)
WO (1) WO2010075239A1 (es)
ZA (2) ZA201103863B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0909625B1 (pt) 2008-03-17 2021-09-08 Actelion Pharmaceuticals Ltd Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
EP3409274B1 (en) 2008-12-22 2019-11-20 Novartis AG Dosage regimen for a s1p receptor agonist
BR112012006957A2 (pt) 2009-09-29 2016-06-14 Novartis Ag regime de dosagem de um modulador de receptor de s1p
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
CN103221391B (zh) 2010-01-27 2018-07-06 艾尼纳制药公司 (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法
CN102917698A (zh) * 2010-05-06 2013-02-06 诺瓦提斯公司 二芳基硫醚衍生物的给药方案
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
PT2661261T (pt) 2011-01-07 2019-10-25 Novartis Ag Formulações imunossupressoras.
DK2675893T3 (en) 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2012162392A1 (en) * 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
TW201320994A (zh) * 2011-10-11 2013-06-01 Novartis Ag 投藥療程
HUE050733T2 (hu) 2012-08-17 2021-01-28 Actelion Pharmaceuticals Ltd Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék
WO2014138502A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
JP6401257B2 (ja) 2013-10-11 2018-10-10 テイコク ファーマ ユーエスエー インコーポレーテッド 局所用スフィンゴシン−１−リン酸受容体アゴニスト製剤及びその使用方法
KR20160141841A (ko) * 2014-04-10 2016-12-09 노파르티스 아게 Ｓ１ｐ 조절제 즉시 방출 투여 요법
SMT202200137T1 (it) 2014-12-11 2022-05-12 Actelion Pharmaceuticals Ltd Regime di dosaggio per ponesimod, un agonista del recettore s1p1 selettivo
JP6895378B2 (ja) * 2015-01-06 2021-06-30 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態の処置方法
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
AU2016284162A1 (en) 2015-06-22 2018-02-01 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2018151834A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
WO2019236757A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
PH12022551043A1 (en) 2019-10-31 2023-05-03 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
WO2021158838A1 (en) 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126658T3 (es) 1992-10-21 1999-04-01 Yoshitomi Pharmaceutical Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
AU2001285331B2 (en) 2000-08-31 2006-04-06 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
EP1955696B1 (en) 2002-05-16 2014-05-28 Novartis AG Use of the EDG receptor binding agent FTY720 in cancer
EP1663188B1 (en) * 2003-09-12 2016-08-10 Newron Sweden AB Treatment of disorders of the nervous system
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP2384749A1 (en) * 2004-11-29 2011-11-09 Novartis AG Dosage regimen of an S1P receptor agonist
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP1850689A4 (en) * 2005-02-10 2013-05-22 G I View Ltd TECHNIQUES FOR DISPLACING A GASTROINTESTINAL TOOL EQUIPPED WITH A GUIDING ELEMENT
SI2952177T1 (sl) * 2007-10-12 2021-07-30 Novartis Ag Sestavki, ki vsebujejo modulatorje receptorja sfingozin 1 fosfata (s1p)
BRPI0909625B1 (pt) * 2008-03-17 2021-09-08 Actelion Pharmaceuticals Ltd Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1
EP3545953A1 (en) * 2008-06-20 2019-10-02 Novartis AG Paediatric compositions for treating1 multiple sclerosis
CN102264363A (zh) 2008-12-22 2011-11-30 诺瓦提斯公司 S1p受体激动剂的给药方案
EP3409274B1 (en) 2008-12-22 2019-11-20 Novartis AG Dosage regimen for a s1p receptor agonist

Also Published As

Publication number Publication date
CL2011001529A1 (es) 2012-02-24
LT3453387T (lt) 2020-08-25
ES2552823T3 (es) 2015-12-02
CY1116990T1 (el) 2017-04-05
UY32352A (es) 2010-07-30
AU2009330176B2 (en) 2014-03-06
JP2024129030A (ja) 2024-09-26
CY2020036I2 (el) 2021-06-25
CR20110274A (es) 2011-07-19
KR101347919B1 (ko) 2014-01-07
TW201028143A (en) 2010-08-01
PT3453387T (pt) 2020-08-11
EP2379067A1 (en) 2011-10-26
BRPI0923500A2 (pt) 2018-05-29
KR20110096175A (ko) 2011-08-29
SI3453387T1 (sl) 2020-10-30
DK3453387T3 (da) 2020-08-10
ES2810823T3 (es) 2021-03-09
IL278914A (en) 2021-01-31
CY2020036I1 (el) 2021-03-12
US20110257133A1 (en) 2011-10-20
IL213170A0 (en) 2011-07-31
MX2011006623A (es) 2011-07-12
US20160263061A1 (en) 2016-09-15
IL274756A (en) 2020-07-30
CY1122812T1 (el) 2021-05-05
EP3409274B1 (en) 2019-11-20
US20180289638A1 (en) 2018-10-11
SI3409274T1 (sl) 2020-03-31
CN102264359A (zh) 2011-11-30
US20160081949A1 (en) 2016-03-24
AR074826A1 (es) 2011-02-16
NZ593065A (en) 2012-11-30
AU2009330176C9 (en) 2017-01-05
EP4098256A1 (en) 2022-12-07
EP3677260A1 (en) 2020-07-08
HRP20201167T1 (hr) 2020-12-11
PE20120337A1 (es) 2012-04-24
US20200330407A1 (en) 2020-10-22
PT2379067E (pt) 2015-12-23
RS59857B1 (sr) 2020-02-28
HUE048717T4 (hu) 2022-02-28
AU2009330176A1 (en) 2011-07-07
HUE048717T2 (hu) 2020-08-28
US20100160259A1 (en) 2010-06-24
HUE026869T2 (en) 2016-08-29
ME03594B (me) 2020-07-20
LT3409274T (lt) 2020-02-10
JP2012513401A (ja) 2012-06-14
US20140148415A1 (en) 2014-05-29
EP3409274A1 (en) 2018-12-05
HN2011001759A (es) 2013-11-26
PL3453387T3 (pl) 2020-11-02
EA201100978A1 (ru) 2012-01-30
MX2021010759A (es) 2022-07-19
ZA201205942B (en) 2013-03-27
EP2379067B1 (en) 2015-09-02
EP3120844A1 (en) 2017-01-25
US20170189353A1 (en) 2017-07-06
FR20C1060I1 (fr) 2020-12-25
SMT202000441T1 (it) 2020-09-10
JP2016135752A (ja) 2016-07-28
CA2747802A1 (en) 2010-07-01
EP3453387A1 (en) 2019-03-13
AU2009330176C1 (en) 2016-12-08
PL3409274T3 (pl) 2020-06-01
ECSP11011222A (es) 2011-08-31
JP7329965B2 (ja) 2023-08-21
TN2011000272A1 (en) 2012-12-17
CL2013001558A1 (es) 2013-10-25
JP2017141238A (ja) 2017-08-17
ES2760607T3 (es) 2020-05-14
LUC00183I2 (es) 2024-07-01
HUE052048T2 (hu) 2021-04-28
HUS2000046I1 (hu) 2020-12-28
EP3453387B1 (en) 2020-06-03
ZA201103863B (en) 2012-10-31
WO2010075239A1 (en) 2010-07-01
US20190091180A1 (en) 2019-03-28
JP2019167360A (ja) 2019-10-03
SI2379067T1 (sl) 2016-01-29
SG171404A1 (en) 2011-07-28
EP2907511A1 (en) 2015-08-19
DK2379067T3 (en) 2015-12-07
PT3409274T (pt) 2019-12-17
CA2747802C (en) 2021-02-09
DK3409274T3 (da) 2019-12-16
CY1123255T1 (el) 2021-10-29
SMT202000054T1 (it) 2020-03-13
PL2379067T3 (pl) 2016-02-29
NO2020038I1 (no) 2020-11-18
RS60666B1 (sr) 2020-09-30
HRP20192175T1 (hr) 2020-03-20
HRP20151190T1 (hr) 2016-01-01
US20220142949A1 (en) 2022-05-12
JP2022103194A (ja) 2022-07-07
MA32981B1 (fr) 2012-01-02
JP2014144970A (ja) 2014-08-14
ME03802B (me) 2021-04-20
LTPA2020005I1 (lt) 2020-12-10
CO6390117A2 (es) 2012-02-29
US20140066657A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
CU20110136A7 (es) Régimen de dosificación para un agonista de los receptores de s1p
UY32350A (es) Régimen de dosificación de un agonista de los receptores de s1p
UY32853A (es) Nuevos compuestos de oxadiazol
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
EA201190021A1 (ru) Модуляторы toll-подобных рецепторов
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
MX366197B (es) Metodo de monitoreo terapeutico de farmacos depuradores de nitrogeno.
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
PE20120998A1 (es) Metodos para el tratamiento del cancer usando antagonistas de notch
CL2013000342A1 (es) Combinaciones de a) un agonistas del receptor beta-3 adrenergico y b) antagonistas del receptor muscarinico para tratar vejiga hiperactiva; un metodo de tratamiento par ala vejiga hiperactiva que comprende la combinacion.
CL2009002017A1 (es) Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria.
NI201400042A (es) 2 - tiopirimidinonas
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
CL2019003249A1 (es) Protocolo mejorado para el tratamiento de nefritis lúpica.
CL2009001139A1 (es) Composicion que comprende un lisofosfolipido para tratar los efectos de la inflamacion.
GT200600040A (es) Nueva forma de sal de un agonista de dopamina
CL2009001018A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo los pacientes un incremento del nivel de creatinina debido a la utilizacion de dronedarona.
CU20130155A7 (es) Régimen de dosificación para un agonista de los receptores de s1p
AR061139A1 (es) Tratamiento de los calores subitos con antagonistas del receptor muscarinico
GT200900332A (es) Compuestos de bencensulfonamida apropiados para tratar transtornos que responden a la modulacion de receptor de dopamina d3
AR062306A1 (es) Milnacipran para el rtamiento de disfuncion cognoscitiva asociada con fibromalgia
CO6400187A2 (es) Tabletas para terapia de combinación
CL2010000497A1 (es) Uso de compuestos derivados de indol para el tratamiento del dolor visceral; compuestos específicos derivados de indol; procedimiento de preparación de un compuesto; composición farmacéutica y uso para el tratamiento de una condición causada por la acción de nos.